Development and current state of the Deep Brain Stimulation market for the treatment of Parkinson's disease in Argentina.
DOI:
https://doi.org/10.47924/neurotarget2025476Keywords:
Deep Brain Stimulation, Parkinson's DiseaseAbstract
The object of analysis of this work consists of the evaluation of the market for deep brain stimulation (DBS) therapy, for the control of symptoms in patients with Parkinson's disease in Argentina, and its evolution in the time.
Metrics
References
Boland DF, Stacy M. The economic and quality of life burden associated with Parkinson’s disease: a focus on symptoms. Am J Manag Care. 2012;18(7 Suppl):S168–75.
Charles PD, Padaliya BB, Newman WJ, Gill CE, Covington CD, Fang JY, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord. 2004;10(8):475–9.
Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord. 2013;28(6):763–71.
deSouza R-M, Moro E, Lang AE, Schapira AHV. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73(5):565–75.
Dowding C.H., Shenton C.L., Salek S.S. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006;23(9):693–721.
Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol. 2014;261(1):106–16.
Feher G, Balas I, Komoly S, Doczi T, Janszky J, Aschermann Z, et al. [Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation]. Ideggyogyaszati Szle. 2010 ;63(9-10):314–9.
Gerzeli S, Cavallo MC, Caprari F, Ponzi P, Albanese A, Ammannati F, et al. Analysis of deep brain stimulation (DBS) costs: An observational study on Italian patients. PharmacoEconomics - Ital Res Artic. 2002;4(2):65–79.
Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R. Pharmacoeconomic considerations of treating patients with advanced Parkinson’s disease. Expert Opin Pharmacother. 2012;13(7):939–58.
Spottke E.A., Volkmann J., Lorenz D., Krack P., Smala A.M., Sturm V., et al. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol. 2002;249(6):759–66.
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, et al. Cost of illness and its predictors for Parkinson 's disease in Germany. PharmacoEconomics. 2005;23(8):817–36.
Maceira D. Dimensiones horizontal y vertical en el aseguramiento social en salud de América Latina y el Caribe. Iniciativas Latinoamericanas (HSPH, FPMD, PHR, PAHO, USAID (2001) Edición especial 3.
Piedimonte F. Reimbursement structure for Neuromodulation Therapies and Technology in South America. Neuromodulation - Second Edition. Comprehensive textbook of principles, technologies and therapies. Volume 3, Academic Press, Section XVI The business end of Neuromodulation, Elsevier (2018) Pag. 1695-1771.
Maceira, D. El sistema de salud argentino en imágenes. Buenos Aires: Fundar (2021) Disponible en https://www.fund.ar
Scherer, F.M. and Ross, David, Industrial Market Structure and Economic Performance (1990). University of Illinois at Urbana-Champaign's Academy for Entrepreneurial Leadership Historical Research Reference in Entrepreneurship, Available at SSRN: https://ssrn.com/abstract=1496716
Maceira D. et. al. Evaluando una estrategia de intervención estatal. La producción pública de medicamentos. Comisión Nacional Salud Investiga (2010). https://www.danielmaceira.com.ar/wp-content/uploads/2014/07/Maceira_et_al_SaludInvestiga-2010-version-9sep20101.pdf
Maceira, D. Mecanismos de pago a prestadores en el sistema de salud: incentivos, resultados e impacto organizacional. Resultados e Impacto Organizativo. Sugerencias para una Agenda de Investigación en los Países en Desarrollo." Documento de Trabajo MAR2, Partnerships for Health Reform, Abt Associates, Bethesda MD, EEUU, Septiembre 1998.
Programa Provincial de Neuromodulación (PPNM) https://www.ms.gba.gov.ar/sitios/neuromodulacion/
Sistema Único de Reintegro (SUR) https://www.argentina.gob.ar/normativa/nacional/resoluci%C3%B3n-1200-2012-202779/ texto
Resolución 1403/2021. RESOL-2021-1403-APN-SSS#MS. Ciudad de Buenos Aires, 17/08/2021. Disponible en: https://www.argentina.gob.ar/normativa/nacional/resoluci%C3%B3n-1403-2021-353175/texto
Sistema Único de Reintegro por Gestión de Enfermedades (SURGE) https://www.argentina.gob.ar/normativa/nacional/resoluci%C3%B3n-731-2023-381402/texto
Bauso DJ, Tartari JP, Stefani CV, Rojas JI, Giunta DH, Cristiano E. Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina. Eur J Neurol. 2012;19(8):1108-1113. doi:10.1111/j.1468-1331.2012.03683.x
Morgante L, Morgante F, Moro E, et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13(8):528-531.doi:10.1016/j.parkreldis.2006.12.013
Larsen. Deep Brain Stimulation & Vagus Nerve Stimulation Devices Market. (2018)
Larsen. Neuromodulation: Deep Brain Stimulation and Vagus Nerve Executive Summary. Meddevicetracker Lead Market Analyst (2020)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fabián Piedimonte
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
